To determine the significance of changes in serum antineuronal antibody levels in systemic lupus erythematosus, 9 patients who had a rise and 11 patients who had a fail in neuronal antibody titre over a mean duration of 2.1 years (range 0.25-5.2) were identified. These changes were examined in the light ofconcurrent changes in other serological variables, overall disease activity, neuropsychiatric disease and neuropsychological tests.
Introduction
Neuropsychiatric (NP) manifestations of systemic lupus erythematosus (SLE) contribute substantially to the morbidity and mortality of the disease. They occur in approximately 50% of patients'`5 and are said to account for up to 19% of deaths.2'6 The features of NP disease vary from overt neurological dysfunction such as psychosis, organic brain syndrome and seizure disorders7'8 to more subtle subclinical defects of neurocognitive function demonstrable by detailed neuropsychological analysis. 4'5'9 There are no specific features of the disease and physicians caring for such patients must therefore rely on their clinical judgement, supported by non-specific laboratory investigations such as cerebrospinal fluid (CSF) examination, electroencephalography, computerized tomographic, radionuclide and other forms of brain scanning7'8 in establishing a diagnosis.
Antineuronal or brain cross-reactive lymphocyte antibodies, which may demonstrate binding to either surface or intracellular antigens, have been associated with NP-SLE in a subset of patients.'0-'9 A pathogenic role for such antibodies is supported by their temporal relationship with NP events,' 113'1516 their presence in both CSF and serum in relation to NP manifestations or cognitive dysfunction4 5"'7 and their detection in neuronal tissues of SLE patients succumbing to NP disease.'2"8 The aim of the present study was to examine the association between changes in serum antibody levels to surface neuronal antigens and NP-SLE, and to determine if this information would assist in the management of some patients with NP disease. Patients who demonstrated a substantial rise or fall in serum IgG antineuronal antibody levels were identified. Changes in antibody levels were examined in the light of other serological variables, overall disease activity and NP manifestations. The selectivity of the rise or fall in antineuronal antibodies was examined by comparing them to concurrent changes in other serological variables. A rise in antineuronal antibodies was more likely than a fall to represent a selective change. The disparity in the ability of the antineuronal antibody response to distinguish between active NP-SLE and quiescent NP-SLE in the two groups is most likely related to the difference in drug therapy. Patients in group A had a slight reduction in their maintenance therapy over the study period, while in group B aggressive immunosuppressive therapy was introduced. Therefore, clinical and serological changes in group A most likely reflect underlying disease activity while those in group B probably reflect the effects of non-specific immunosuppression.
Materials and methods

Patients
There is a lack ofconsensus concerning the degree of involvement of the central nervous system in SLE and its various manifestations. Overt features of NP-SLE have been recognized by many investigators, 1-3,7,8 while we,4'5 and others,9 have also reported more subtle abnormalities, which are frequently subclinical, and not attributable to chronic disease or psychological distress, detected by detailed neuropsychological testing. In the present study we attempted to examine changes in both overt and subtle NP disease by using a modified clinical classification of NP-SLE culled from previous classifications,'3 and results of neuropsychological tests which were available in a limited number of patients. Using the former classification, 8 patients had evidence of NP-SLE over the study period. Clinical improvement or deterioration in NP-SLE occurred concurrently with a fall or rise in antineuronal antibodies respectively in 6 of these patients. Furthermore, significant changes in sequential neuropsychological testing in 4 patients showed 100% concordance with changes in antineuronal antibody levels. Therefore, there was a consistent correlation between changes in NP disease and neuropsychological testing and concurrent changes in antineuronal antibody levels, although a similar correlation was also frequently seen with anti-DNA antibody levels.
It is generally agreed that antineuronal antibodies do not represent the only potential pathogenic mechanism in NP-SLE."7'78"2 The evidence implicating their role in the pathogenesis of the disease is still largely circumstantial. It is likely that in some patients with SLE the presence of such antibodies, as detected by current assays, may reflect the presence of polyclonal activation, cross-reactive autoantibodies or a secondary response to neuronal damage. Therefore, in an attempt to improve the diagnostic specificity and to further our understanding of antineuronal antibodies in NP-SLE, efforts have been made to identify the antigenic specificities of these antibodies. In a recent study, Bonfa et al. '6 reported the presence of antiribosomal P protein antibodies in 18 of 20 patients with lupus psychosis, as defined by a behavioural disturbance lasting 2 weeks and requiring hospitalization and psychotropic medications. Overall, this antibody is present in 12% of SLE patients, 50% of whom have psychosis by this definition. The target antigen of the anti-P antibody is intra-cellular in origin and its reactivity is not restricted to neuronal cells. Our antineuronal antibody assay reflects binding to surface neuronal antigens, among which at least one high molecular weight antigen (97K) is unique to neuronal cells and precipitated only by SLE sera.24 Further work is needed to determine the clinical and pathogenic significance of this finding.
